|Title:||2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations||Authors:||Yu M.-L.
|Issue Date:||2020||Publisher:||Elsevier B.V.||Journal Volume:||119||Journal Issue:||7||Start page/Pages:||1135-1157||Source:||Journal of the Formosan Medical Association||Abstract:||
Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been reported in Taiwan, especially in high-risk populations including people who inject drugs (PWID) and patients requiring dialysis. Besides, certain populations merit special considerations due to suboptimal outcome, potential drug–drug interaction, or possible side effect. Therefore, in the second part of this 2-part consensus, the Taiwan Association for the Study of the Liver (TASL) proposes the treatment recommendations for the special population in order to serve as guidance to optimizing the outcome in the direct-acting antiviral (DAA) era. Special populations include patients with acute or recent HCV infection, previous DAA failure, chronic kidney disease, decompensated cirrhosis, HCC, liver and other solid organ transplantations, receiving an HCV viremic organ, hepatitis B virus (HBV) and HCV dual infection, HCV and human immunodeficiency virus (HIV) coinfection, active tuberculosis infection, PWID, bleeding disorders and hemoglobinopathies, children and adolescents, and pregnancy. Moreover, future perspectives regarding the management of hepatitis C are also discussed and summarized in this consensus statement. ? 2020 Formosan Medical Association
|ISSN:||0929-6646||DOI:||10.1016/j.jfma.2020.04.002||metadata.dc.subject.other:||antivirus agent; acute hepatitis C; antiviral therapy; Article; bleeding disorder; chronic kidney failure; clinical outcome; consensus; decompensated liver cirrhosis; drug interaction; graft recipient; heart transplantation; hemoglobinopathy; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; high risk population; human; Human immunodeficiency virus infection; infection risk; injection drug user; intestine transplantation; kidney transplantation; liver cell carcinoma; liver transplantation; lung transplantation; medical society; mixed infection; nonhuman; organ transplantation; pancreas transplantation; population research; special situation for pharmacovigilance; Taiwan; treatment indication; tuberculosis; adolescent; child; chronic hepatitis C; complication; consensus; female; Hepacivirus; hepatitis C; liver cell carcinoma; liver tumor; mixed infection; practice guideline; pregnancy; Adolescent; Antiviral Agents; Carcinoma, Hepatocellular; Child; Coinfection; Consensus; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Pregnancy; Taiwan
|Appears in Collections:||臨床醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.